1. World Drug Report 2021. United Nations Publication. WDR21_Booklet_1.pdf (unodc.org), 2021.
2. Strang J, Darke S, Hall W, Farrell M, Ali R: Heroin overdose: the case for take-home naloxone. BMJ 1996, 312(7044):1435-1436.
3. Strang J, Bird SM, Dietze P, Gerra G, McLellan AT: Take-home emergency naloxone to prevent deaths from heroin overdose. BMJ 2014, 349:g6580.
4. World Health Organization: Community management of opioid overdose: Geneva: World Health Organization; 2014.
5. Walley AY, Xuan Z, Hackman HH, Quinn E, Doe-Simkins M, Sorensen-Alawad A, Ruiz S, Ozonoff A: Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: interrupted time series analysis. BMJ 2013, 346:f174.
6. Langham S, Wright A, Kenworthy J, Grieve R, Dunlop WCN: Cost-Effectiveness of Take-Home Naloxone for the Prevention of Overdose Fatalities among Heroin Users in the United Kingdom. Value Health 2018, 21(4):407-415.
7. Coffin PO, Sullivan SD: Cost-effectiveness of distributing naloxone to heroin users for lay overdose reversal. Ann Intern Med 2013, 158(1):1-9.
8. Cipriano LE, Zaric GS: Cost-effectiveness of naloxone kits in secondary schools. Drug Alcohol Depend 2018, 192:352-361.
9. Siegler A, Huxley-Reicher Z, Maldjian L, Jordan R, Oliver C, Jakubowski A, Kunins HV: Naloxone use among overdose prevention trainees in New York City: A longitudinal cohort study. Drug Alcohol Depend 2017, 179:124-130.
10. Rowe C, Santos GM, Vittinghoff E, Wheeler E, Davidson P, Coffin PO: Predictors of participant engagement and naloxone utilization in a community-based naloxone distribution program. Addiction 2015, 110(8):1301-1310.
11. Clark AK, Wilder CM, Winstanley EL: A systematic review of community opioid overdose prevention and naloxone distribution programs. J Addict Med 2014, 8(3):153-163.
12. Katzman JG, Takeda MY, Greenberg N, Moya Balasch M, Alchbli A, Katzman WG, Salvador JG, Bhatt SR: Association of Take-Home Naloxone and Opioid Overdose Reversals Performed by Patients in an Opioid Treatment Program. JAMA Netw Open 2020, 3(2):e200117.
13. Winstanley EL, Clark A, Feinberg J, Wilder CM: Barriers to implementation of opioid overdose prevention programs in Ohio. Subst Abus 2016, 37(1):42-46.
14. Davis CS, Carr D: Legal changes to increase access to naloxone for opioid overdose reversal in the United States. Drug Alcohol Depend 2015, 157:112-120.
15. Norwegian Directorate of Health. Overdose prevention Strategy 2014. "Sure you can quit drugs, but first you have to survive.” Norwegian Directorate of Health 2014.
16. Madah-Amiri D, Clausen T, Lobmaier P: Rapid widespread distribution of intranasal naloxone for overdose prevention. Drug Alcohol Depend 2017, 173:17-23.
17. Madah-Amiri D, Clausen T, Lobmaier P: Utilizing a train-the-trainer model for multi-site naloxone distribution programs. Drug Alcohol Depend 2016, 163:153-156.
18. Bendel RB, Afifi AA: Comparison of Stopping Rules in Forward "Stepwise" Regression. Journal of the American Statistical Association 1977, 72(357):46-53.
19. Martins SS, Sampson L, Cerdá M, Galea S: Worldwide Prevalence and Trends in Unintentional Drug Overdose: A Systematic Review of the Literature. Am J Public Health 2015, 105(11):29.
20. Kenney SR, Anderson BJ, Bailey GL, Stein MD: Factors associated with naloxone administration in an opioid dependent sample. J Subst Abuse Treat 2018, 84:17-20.
21. Gjersing L, Bretteville-Jensen AL: Patterns of substance use and mortality risk in a cohort of 'hard-to-reach' polysubstance users. Addiction 2018, 113(4):729-739.